MARKET

APLS

APLS

Apellis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.79
-1.89
-6.59%
Closed 18:53 03/31 EDT
OPEN
28.96
PREV CLOSE
28.68
HIGH
29.66
LOW
26.39
VOLUME
686.67K
TURNOVER
--
52 WEEK HIGH
45.04
52 WEEK LOW
16.85
MARKET CAP
2.02B
P/E (TTM)
-4.6642
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average APLS stock price target is 50.92 with a high estimate of 86.00 and a low estimate of 29.00.

EPS

APLS News

More
  • Mizuho sees 86% upside in Sarepta in premarket analyst action
  • Seeking Alpha - Article · 21h ago
  • BMO Capital Initiates Coverage On Apellis Pharmaceuticals with Outperform Rating, Announces Price Target to $54
  • Benzinga · 22h ago
  • 3 Dirt-Cheap Healthcare Stocks to Buy Right Now
  • MotleyFool.com · 4d ago
  • Should You Buy These 3 Dirt-Cheap Stocks?
  • MotleyFool.com · 5d ago

Industry

Pharmaceuticals
-0.13%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About APLS

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. It is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The Company is developing APL-9 for intravenous administration in systemic indications.
More

Webull offers kinds of Apellis Pharmaceuticals Inc stock information, including NASDAQ:APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions.